As cannabis policy reform gains momentum across the United States and globally, a critical aspect of the conversation is often overlooked—medical marijuana. While adult-use (recreational) legalization captures much of the public and legislative attention, the foundational role of medical cannabis remains underemphasized in policy debates. Luna Stower, chief impact officer at Ispire and an influential voice in the cannabis industry, argues that medical cannabis must be at the forefront of policy discussions due to its unique therapeutic potential and impact on public health. Stower, a speaker at the upcoming Benzinga Cannabis Capital Conference, has long championed the importance of medical cannabis in both national and international policy frameworks.
Medical Cannabis: The Bedrock of the Cannabis Movement
Despite the rapid growth and substantial revenue potential of recreational cannabis markets, medical marijuana remains a cornerstone for countless patients managing a wide variety of health conditions. According to Stower, the significance of medical cannabis extends beyond revenue—it’s about providing essential relief to patients suffering from conditions like chronic pain, epilepsy, PTSD, and other debilitating illnesses.
Data-Driven Evidence of Therapeutic Benefits
Research consistently supports the therapeutic benefits of medical marijuana. A study in the Journal of Pain Research found that cannabis use led to a 64% reduction in opioid use among chronic pain patients, while another study published in Epilepsy & Behavior demonstrated that cannabidiol (CBD), a non-psychoactive component of cannabis, significantly reduced seizure frequency in children with treatment-resistant epilepsy. Furthermore, a 2021 meta-analysis published in the British Journal of Clinical Pharmacology indicated that cannabis was effective in reducing neuropathic pain symptoms in patients who did not respond to conventional treatments.
These findings not only support the integration of medical cannabis into treatment protocols but also highlight its potential role in combating the opioid crisis. The Centers for Disease Control and Prevention (CDC) reported that the opioid crisis continues to claim over 90,000 lives annually in the U.S. alone. By offering an alternative to opioids, medical cannabis could serve as a harm reduction tool, potentially decreasing dependency and overdose rates.
Legislative Disparities: Why Medical Cannabis is Overlooked
Despite its proven benefits, medical cannabis is often deprioritized in recent legislative efforts. Instead, states are focusing on adult-use legalization due to its substantial economic benefits. This shift has led to a concerning trend where medical cannabis programs are being overshadowed, risking the loss of access for patients who rely on it for critical health conditions.
For instance, a 2020 study published in Health Policy noted that states with dual medical and recreational markets saw a significant decline in the number of registered medical cannabis patients. In Colorado, the number of registered patients dropped by 34% within two years of launching its recreational market. This decline suggests that patients may be abandoning medical cannabis programs due to increased costs and reduced availability of specialized products, potentially hindering their ability to access necessary treatments.
Stower stresses that this shift not only undermines the purpose of medical cannabis but also fails to recognize its distinct role in public health. She warns that overemphasis on recreational cannabis could marginalize patients and limit their access to the medical-grade products and guidance they need.
Global Recognition of Medical Marijuana: Opening the Door for Reform
While the U.S. struggles to balance medical and recreational cannabis markets, other countries are using medical marijuana as a stepping stone to broader reform. In nations like Germany and Israel, medical cannabis programs have laid the groundwork for regulatory changes that prioritize patient care and establish high-quality standards for cultivation and distribution.
International Case Studies
Germany’s medical cannabis program, which started in 2017, quickly became one of the most robust in Europe. By 2020, over 128,000 patients were enrolled in the program, benefiting from government-regulated access to cannabis for conditions ranging from chronic pain to anorexia. Similarly, Israel’s long-standing medical cannabis program, initiated in the early 1990s, has produced extensive research that continues to inform global cannabis policy. Israel’s Health Ministry-approved cannabis use for PTSD, based on studies indicating a 75% reduction in symptoms among patients.
These international examples demonstrate how focusing on medical cannabis can pave the way for broader acceptance and integration of cannabis into healthcare systems. The World Health Organization (WHO) acknowledged the therapeutic potential of cannabis in its 2020 recommendation to reschedule cannabis, a move that many nations, including Thailand and Argentina, have used as a basis for introducing or expanding their medical marijuana programs.
The Ongoing Need for Advocacy: Ensuring Medical Cannabis Stays Relevant
As the cannabis industry evolves, it’s crucial to maintain advocacy for medical marijuana as a distinct policy issue. Stower emphasizes that while the commercial potential of recreational cannabis is undeniable, it should not overshadow the unique contributions medical cannabis makes to public health. Advocacy groups such as Americans for Safe Access and the International Association for Cannabinoid Medicines have long argued for maintaining distinct frameworks for medical and recreational cannabis to ensure that patients’ needs are prioritized.
Evidence-Based Advocacy and Policy Change
A 2018 study in Health Affairs found that states with comprehensive medical marijuana programs experienced a 5.88% reduction in opioid prescriptions. Such data-driven insights are vital for advocacy efforts, providing a compelling argument for policymakers to consider the unique benefits of medical cannabis. Advocacy efforts should focus on presenting these data to ensure that medical cannabis retains its rightful place in legislative frameworks, especially as new states and countries look to establish or expand cannabis programs.
Conclusion: Bringing Medical Marijuana Back to the Forefront
Stower’s perspectives underscore the need to refocus on medical marijuana’s role in cannabis policy discussions. As the cannabis market continues to mature, it is crucial to ensure that the foundational goals of the movement—patient care and public health—do not get lost in the pursuit of profits. The upcoming Benzinga Cannabis Capital Conference will provide a platform for these critical conversations, allowing industry leaders to explore the future of cannabis policy, investment, and market trends, with medical marijuana advocacy at the heart of the dialogue.
By leveraging robust research and patient-centered advocacy, the cannabis community can ensure that medical marijuana remains a core part of the conversation, both in the United States and around the world. This is essential not only for preserving access for patients but also for the continued development of cannabis as a respected therapeutic option in the global healthcare landscape.
COMMENTS